Author Archive: BIOtechNOW Editor

Auto Injectors & Pen Injectors: Differentiating Products in Asia Pacific

Steven Kaufman

Asia Pacific, with its mix of mature and emerging pharmaceutical markets and strong indigenous R&D capabilities, has no doubt already become a prominent driving force for the current and future global pharmaceutical industry with reports projecting the industry in this region to grow at a CAGR of 10 percent between 2012 and 2015. As the third largest pharmaceutical market following North America and Europe, Asia Pacific offers an immense potential for multinational pharmaceutical companies not Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

What’s Behind the Rise in Executive Liability Insurance Prices?

Joe Haltman

What do gas, milk, bacon, electricity and now your Directors and Officers Liability Insurance coverage have in common? It may sound like the start of a bad joke but, in fact, they’re all goods or services that cost more than they used to. Some of you may have noticed that the price of Directors and Officers Liability, or D&O Insurance, is going up. Companies and organizations across the biotechnology sector are seeing price increases, with Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , ,

Delivering on the Promise of Personalized Medicine

185x185_ad_btn_home

As sequencing moves out of the lab and into the clinic, a host of players must get involved to make our collective promises of personalized medicine a reality. CEOs, entrepreneurs, researchers, clinicians, regulators and payers need to work together to take on the next challenges in the implementation of personalized medicine. Some of those challenges include: Cost vs. Benefit: How do we define and benefit from transformational technologies? Form vs. Function: What about the less Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

The Future of Biodefense: Will Public-Private Partnerships Continue?

commercial-jenn

Ten years ago, in the wake of the 2001 anthrax attacks, the U.S. government set out on a bold path to improve the country’s preparedness for bioterrorism by developing and stockpiling new drugs and vaccines to protect Americans from health emergencies.  Individuals from both political parties – many who had experienced bioterror first hand – worked together to harness the power of innovative science and tackle this national security threat. The ten year initiative was Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Inter Partes Review – a Useful Tool for Overcoming Freedom-to-Operate Obstacles

Basic CMYK

By Eric K. Steffe, Eldora L. Ellison, Ph.D., Todd Spalding, and Deborah A. Sterling, Ph.D. For companies facing freedom-to-operate obstacles, the AIA provides a number of tools for dealing with troublesome patents.  While proceeding at risk in the face of such patents sometimes make sense, inter partes review (IPR) provides a viable option for challenging them and should be considered as a valuable addition to one’s freedom-to-operate toolbox. Inter partes reexamination (IPX), which (bio)pharma used Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,